Literature DB >> 30376179

Risk factors for treatment failure in scabies: a cohort study.

A Aussy1, E Houivet2, V Hébert1, H Colas-Cailleux1, N Laaengh1, C Richard1, M Ouvry1, C Boulard1, S Léger1, N Litrowski1, J Benichou2, P Joly1.   

Abstract

BACKGROUND: Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries.
OBJECTIVES: To identify predictors of treatment failure of scabies in ambulatory populations.
METHODS: This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment.
RESULTS: In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2·15, 95% confidence interval (CI) 1·22-3·77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10·2. 95% CI 4·49-23·2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4·31, 95% CI 1·89-9·84); (iv) absence of decontamination of furnishings (OR 8·72, 95% CI 3·50-21·8), in particular sofa and cushions (OR 5·90, 95% CI 2·34-14·9), mattresses (OR 4·16, 95% CI 1·35-12·8) or car seats (OR 6·57, 95% CI 3·27-13·2) and (v) absence of written documents explaining treatment modalities (OR 5·18, 95% CI 2·57-10·4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6·62, 95% CI 2·71-16·2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3·51, 95% CI 1·55-7·95) and (iii) absence of decontamination of furniture with acaricides (OR 5·81, 95% CI 1·96-16·7).
CONCLUSIONS: Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
© 2018 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30376179     DOI: 10.1111/bjd.17348

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  In Vitro Activity of Beauvericin against All Developmental Stages of Sarcoptes scabiei.

Authors:  Charbel Al Khoury; Nabil Nemer; Georges Nemer; Mazen Kurban; Charlotte Bernigaud; Katja Fischer; Jacques Guillot
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 2.  Scabies: Epidemiology, Diagnosis, and Treatment.

Authors:  Cord Sunderkötter; Johannes Wohlrab; Henning Hamm
Journal:  Dtsch Arztebl Int       Date:  2021-10-15       Impact factor: 8.251

3.  Spectrum of skin diseases in Maroon villages of the Maroni area, French Guiana.

Authors:  Julie Valentin; Florence Niemetzky; Melanie Gaillet; Celine Michaud; Aurel Carbunar; Magalie Demar; Pierre Couppie; Romain Blaizot
Journal:  Int J Dermatol       Date:  2022-06-29       Impact factor: 3.204

Review 4.  The Management of Scabies in the 21st Century: Past, Advances and Potentials.

Authors:  Charlotte Bernigaud; Katja Fischer; Olivier Chosidow
Journal:  Acta Derm Venereol       Date:  2020-04-20       Impact factor: 3.875

5.  Mass drug administration campaigns for scabies and impetigo: protocol for a systematic review and meta-analysis.

Authors:  Pousali Ghosh; Wubshet Tesfaye; Avilasha Manandhar; Thomas Calma; Mary Bushell; Victor M Oguoma; Sam Kosari; Faye McMillan; Greg Peterson; Jackson Thomas
Journal:  BMJ Paediatr Open       Date:  2021-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.